Olema Oncology Reports Preclinical Antitumour Activity of KAT6A Degraders in Breast Cancer Models

19 November 2026 | Thursday | News

Olema Oncology will present preclinical findings on four selective KAT6A degraders at the EORTC-NCI-AACR Symposium in Barcelona. The experimental compounds demonstrated tumour regression or growth inhibition in ER-positive, HER2-negative breast cancer models, including those with ESR1 mutations, alongside oral bioavailability and tolerability findings that support further development.
Image Source: Public Domain

Image Source: Public Domain

Olema Oncology, Inc. (“Olema,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond,  announced preclinical data on a series of selective KAT6A degraders in estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer models. The findings will be presented in a poster session at the 38th EORTC-NCI-AACR (ENA) Symposium, held November 18-20, 2026 in Barcelona, Spain.

“We are encouraged by these preclinical findings that support the potential of our highly potent and specific KAT6A degraders as a new therapeutic approach for patients with ER+/HER2- breast cancer,” said David C. Myles, Ph.D., Chief Scientific Officer of Olema Oncology. “Taken together with favorable pharmacokinetics and oral bioavailability, the robust antitumor activity observed across both ESR1-mutant and wild-type in vivo models demonstrates their broad potential. We look forward to the further evaluation of these KAT6A degraders as we explore broadening our pipeline of novel therapies for breast cancer and beyond to complement our KAT6 inhibitor, OP-3136.”

KAT6A and KAT6B are distinct components of an epigenetic regulatory complex that controls transcription. Higher KAT6A expression is associated with poorer outcomes in ER+/HER2- breast cancer. Targeted degradation may eliminate KAT6A's scaffolding functions and transcriptional activity. Four bifunctional small-molecule degraders, OP-1 through OP-4, were evaluated in preclinical models measuring in vitro degradation, selectivity, proliferation, and transcriptional analyses with in vivo xenograft studies.

Key Findings
Selective protein degradation is a novel and effective approach to targeting the KAT6 epigenetic regulatory complex. All four degraders:

  • Demonstrated potent and near-complete proteasome-dependent degradation of only KAT6A with minimal effect on off-target substrates.
  • Caused substantial inhibition of cell proliferation across a diverse range of ER+/HER2- breast cancer models and demonstrated on-target down-regulation of H3K23Ac and ER-alpha protein levels, with superior responses observed compared to the orthosteric inhibitor, prifetrastat.
  • Produced tumor regression as monotherapy in the T47D model and significant tumor growth inhibition in the MCF7 and ST941 models.
  • Were well-tolerated in the xenograft studies across all groups.
  • Showed good oral bioavailability, suggesting the potential of once-daily oral dosing in humans.

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close